ROS1 and non-small cell lung carcinoma: This result is consistent with recently data reported by Scheffler et al. (2015): ROS1 seems to be one of the best prognostic molecular markers in NSCLC and stays in line of recent reports pointing the high efficacy of Crizotinib treatment for these patients [29, 30].